title: Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure.
abstract: BACKGROUND
  Pulmonary arterial hypertension (PAH) is typically distinguished from pulmonary venous hypertension (PVH) by documenting a pulmonary capillary wedge pressure (PCWP) <or= 15 mm Hg. However, PCWP has uncertain utility in establishing PAH. We sought to determine the calibration, discrimination, and diagnostic accuracy of PCWP, using simultaneously measured left ventricular end-diastolic pressure (LVEDP) as the "gold standard."
  
  
  METHODS
  We examined hemodynamic data from the 11,523 unique patients undergoing simultaneous right-heart and left-heart catheterization at a large academic center from 1998 to 2007.
  
  
  RESULTS
  Among 4,320 patients (37.5%) with pulmonary hypertension (PH) [mean pulmonary artery pressure, >or= 25 mm Hg], hemodynamic data were complete for 3,926 patients (90.9%). Of these, 580 patients (14.8%) met the criteria for PAH with a PCWP <or= 15 mm Hg, but 310 of these patients (53.5%) had an LVEDP > 15 mm Hg. Such discrepancies remained common among patients with a pulmonary vascular resistance > 3 Wood units and those being catheterized specifically to evaluate PH. PCWP provided moderate discrimination between patients with high vs normal LVEDP (area under the receiver operating characteristic curve, 0.84; 95% confidence interval, 0.81 to 0.86) but was poorly calibrated to LVEDP (Bland-Altman limits of agreement, - 15.2 to 9.5 mm Hg; Hosmer-Lemeshow goodness-of-fit chi(2) statistic, 155.4; p < 0.0001).
  
  
  CONCLUSIONS
  Roughly half of the patients presumed to have PAH based on PCWP may be found to have PVH based on LVEDP. Reliance on PCWP may result in the dangerous or cost-ineffective use of pulmonary vasodilators for patients with left-heart disease. Furthermore, without assessing LVEDP, investigators may include patients with left-heart disease in therapeutic trials of PAH drugs, thereby limiting their ability to detect beneficial drug effects.
authors.affiliation: Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA. Electronic address: scott.halpern@uphs.upenn.edu.
authors.forename: Scott D
authors.initials: SD
authors.lastname: Halpern
authors.affiliation: Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.
authors.forename: Darren B
authors.initials: DB
authors.lastname: Taichman
mesh_terms: D015331:Cohort Studies; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification* / Q000175:diagnosis* / Q000503:physiopathology; D011237:Predictive Value of Tests; D011651:Pulmonary Artery; D011667:Pulmonary Veins; D011669:Pulmonary Wedge Pressure; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012720:Severity of Illness Index; D014690:Venous Pressure; D016277:Ventricular Function, Left / Q000502:physiology*; D017725:Ventricular Pressure